ArticleLife sciences2020
Immunocytometric analysis of COVID patients: A contribution to personalized therapy?
Article in Life sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Matrix metalloproteinases (MMP) 3 and 9 as biomarkers of severity in COVID-19 patients.Scientific reports · 2022Trial
- Serum HDL subfractions are impaired by COVID-19 vaccine in patients with thymic epithelial tumors.Scientific reports · 2026Article
- Serum HDL and their subfractions are impaired in multisystem inflammatory syndrome in children (MIS-C).Journal of translational medicine · 2025Article
- Inflammatory Biomarkers Demonstrate Predictive Capacity for Mortality in COVID-19-Related ARDS Patients Receiving High-Dose Corticosteroids: A Longitudinal Analysis.Journal of inflammation research · 2025Article
- Immune Profile in COVID-19: Unveiling TInternational journal of molecular sciences · 2024Article
- Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response.Frontiers in immunology · 2023Article
- Dysregulated thrombospondin 1 and miRNA-29a-3p in severe COVID-19.Scientific reports · 2022Article
- A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19.Vaccines · 2022Article
- Evaluation of individual and combined NLR, LMR and CLR ratio for prognosis disease severity and outcomes in patients with COVID-19.International immunopharmacology · 2022Article
- Lymphocyte Population Changes at Two Time Points during the Acute Period of COVID-19 Infection.Journal of clinical medicine · 2022Article
- Biomarkers of Endothelial Damage in Distinct Phases of Multisystem Inflammatory Syndrome in Children.Metabolites · 2022Article
- Therapeutic strategies to fight COVID-19: Which is the status artis?British journal of pharmacology · 2022Review
- Inducible Nitric Oxide Synthase (iNOS): Why a Different Production in COVID-19 Patients of the Two Waves?Viruses · 2022Article
- Immunophenotyping of peripheral blood cells allows to discriminate MIS-C and Kawasaki disease.Translational medicine communications · 2022Article
- MIS-C: A COVID-19-as sociated condition between hypoimmunity and hyperimmunity.Frontiers in immunology · 2022Article
- Immune and pathophysiologic profiling of antenatal coronavirus disease 2019 in the GIFT cohort: A Singaporean case-control study.Frontiers in pediatrics · 2022Article
- Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant.Biomolecules · 2021Article
- Does immune recognition of SARS-CoV2 epitopes vary between different ethnic groups?Virus research · 2021Article
- Cytometric analysis of patients with COVID-19: what is changed in the second wave?Journal of translational medicine · 2021Article
- Further Findings Concerning Endothelial Damage in COVID-19 Patients.Biomolecules · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aims to cast light on immunocytometric alterations in COVID-19, a potentially fatal viral infection with heterogeneous clinical expression and a not completely defined pathophysiology.
methodsWe studied 35 COVID patients at hospital admission testing by cytofluorimetry a large panel of lymphocyte subpopulations and serum tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-17A and the soluble receptor of IL-17A (IL-17RA). KEY
findingsAt hospital admission, total lymphocytes and most T and B subpopulations were reduced in 50-80% of patients, with close relationship to disease severity. While activated T helper 1 (TH1) and TH17 cells resulted normal or higher. Serum IL-6 was increased in all patients, while TNF-α and IL-17A were higher in advanced stages. A patient subset with low severity had very high IL-17RA levels. Tocilizumab treatment caused an increase of IL-17A in 3/6 patients and a reduction in 3 others, while the lymphocyte number increased in 3 patients and did not change in the others. SIGNIFICANCE: Cytofluorimetry revealed a functional exhaustion of most lymphocyte populations in COVID patients not involving activated TH1 and TH17. Consequently, there was a relevant cytokines production that contributes to impair the respiratory inflammation. The increase of TH17 and IL-17 in a subset of cases and the evidence of a significant increase of IL-17RA (that prevents the interaction of IL-17 with the cell receptor) in patients with low severity suggest that some patients could benefit from monoclonal antibodies treatment targeting IL-17 pathway. Immunocytofluorimetric markers may contribute to a personalized therapy in COVID patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.